Toolgen said Friday that it has completed the registration of two German utility models related to its genome-editing tool called Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR).
The German utility model is an intellectual property right that protects inventions. It is similar to a patent but differs in that it takes less time to secure and entitles only the user to use, manufacture or market products related to the utility model.
CRISPR is a vital tool in gene correction technology capable of cutting strands of DNA and selectively correct specific genetic information in cells. It is widely used in life sciences because it can selectively correct specific genetic information in cells.
The utility model filed by the company includes essential source technology for the use of the “CRISPR gene scissors” in the field of gene correction and technology for enhancing its accuracy.
The company has also already completed its patent registration in 10 countries, including the U.S., Europe, and Japan, and confirmed its competitiveness through receiving patents from Korea and Australia last year.
Monsanto, the world's largest seed company, and Thermo Fisher Scientific, a global company in the field of products and services for life sciences research, have licensed out Toolgen’s technology.
<© Korea Biomedical Review, All rights reserved.>